Clinical Trials Logo

Obesity; Endocrine clinical trials

View clinical trials related to Obesity; Endocrine.

Filter by:

NCT ID: NCT06357273 Completed - Obesity Clinical Trials

The Effect of White Tea Consumption on Obesity

Start date: July 1, 2023
Phase:
Study type: Observational

Obesity is an increasing global public health issue. In general, tea consumption have been shown to offer benefit to obese patients. However, the potential of white tea (WT) to treat and protect from the adverse effects of obesity have not been addressed so far. The aim of this study was to examine the efficacy and impact WT consumption highest in catechins on levels of anthropometric and biochemical values in obese patients.

NCT ID: NCT05676229 Recruiting - Obesity Clinical Trials

Probiotic Blend in Reducing Anthropometric Measurements in Obese Adults

Start date: January 11, 2023
Phase: Phase 2
Study type: Interventional

It is already known that dysbiosis, that is, qualitative and quantitative changes in the composition of the intestinal microbiota, can be associated with the development of a series of intestinal and extra-intestinal disorders. Dysbiosis is reported in irritable bowel syndrome, inflammatory bowel disease, colorectal cancer, allergic diseases, non-alcoholic steatohepatitis, arteriosclerotic diseases, neurological diseases and metabolic syndromes, mainly diabetes and obesity. Among the many factors that play a key role in obesity, a number of studies show the intestinal microbiota as an important contributor. Many studies carried out with probiotics have shown that their administration can be effective in the prevention and treatment of obesity. Furthermore, it is found that benefits for body weight, abdominal adiposity, anthropometric measurements and body composition are often associated with favorable metabolic effects.

NCT ID: NCT05322551 Recruiting - PreDiabetes Clinical Trials

Molecular, Metabolomic and Nutritional Changes After Metabolic Surgery

MoMen
Start date: June 24, 2022
Phase:
Study type: Observational

Obesity is a major risk factor for Type 2 Diabetes (T2D) and cardiovascular diseases, such as hypertension and dyslipidemia. Recently, weight loss surgery (i.e., metabolic or bariatric surgery) has been shown to result in very good long-term glycemic control in patients with T2D and obesity. However, knowledge and data on molecular levels and metabolomics are still limited. This study will fill in these gaps and provide potential biomarkers for T2D. Lifestyle and dietary practices (LDP) influence the clinical outcome and metabolites in T2D. Although the roles of LDP is critical in ensuring optimal clinical outcomes, data is still limited especially on relating the LDP and metabolomics in T2D.

NCT ID: NCT04924738 Recruiting - Clinical trials for Hypertension in Pregnancy

Female Obesity Cohort and Intervention Study Group (MOCART Study Group)

MOCART
Start date: December 3, 2017
Phase:
Study type: Observational

This prospective observational trial includes women with high risk pregnancies complicated with hyperglycemia in pregnancy and excessive body weight. The participants are enrolled when pregnant and monitored throughout pregnancy and delivery until the offspring is 6 months old. This research addresses the question which risk factors for non-communicable disorders such as hypertension, obesity, type 2 diabetes for a woman and her offspring can be detected during pregnancy and in early childhood.

NCT ID: NCT04573998 Recruiting - Obesity; Endocrine Clinical Trials

Study on the Mechanism of lcn2 in Obesity

Start date: July 1, 2016
Phase:
Study type: Observational

Obesity is now becoming a worldwide serious problem. Obesity is associated with a spectrum of severe diseases, including diabetes, cardiovascular diseases, and cancers. Lipocalin 2 (LCN2), also known as neutrophil gelatinase associated lipocalin (NGAL), is a member of the lipocalin family. Due to its upregulated expression in infection, LCN2 is originally considered to be a key regulator of immune response. Subsequent investigations revealed that LCN2 is expressed in many tissues and is related to a variety of diseases, including obesity. LCN2 was reported to be increased in obesity individuals. Thus, the investigators decide to investigate the relationship between LCN2 and obesity.

NCT ID: NCT04417582 Recruiting - Obesity Clinical Trials

Life Style Modification Medical and Surgical Management in Patients With Obesity

Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

In this is an observational study, obese patients that administed and followed in endocrinology clinic of Marmara University Medical school hospital will follow for clinical and laboratory parameters prospectively for 5 years

NCT ID: NCT04305093 Completed - Hormone Disturbance Clinical Trials

Data Mining: Precision Analytical Retrospective Data Correlation

Start date: December 15, 2019
Phase:
Study type: Observational

Data from previously analyzed clinical samples tested by Precision Analytical, Inc. will be mined to identify and select samples from patients reporting hormone supplement use. Patient demographics (BMI, for example), different therapies and expected changes in hormone levels will be analyzed and hormone metabolite patterns will be compared. Samples will be deidentified prior to analysis.

NCT ID: NCT04100616 Recruiting - Obesity Clinical Trials

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obesity

Start date: March 2, 2020
Phase:
Study type: Observational [Patient Registry]

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding obesity.

NCT ID: NCT04019860 Completed - Obesity; Endocrine Clinical Trials

Time-restricted Eating and High Intensity Interval Training Among Women

Start date: August 12, 2019
Phase: N/A
Study type: Interventional

This project will determine the independent and combined effects of high intensity interval training and time-restricted eating on blood sugar regulation among women in reproductive-age who have overweight or obesity. The intervention period will be seven weeks. Before and after the intervention, blood sugar regulation, body composition and physical fitness will be measured and compared between groups who are doing either high intensity interval training, time-restricted eating, both high intensity interval training and time-restricted eating, or who are in a control group. Physical activity, sleep quality, continuous glucose monitoring, adherence to the interventions and hunger/satiety will also be measured.

NCT ID: NCT03650790 Completed - Pre-Eclampsia Clinical Trials

C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies

CTRP
Start date: September 3, 2018
Phase: N/A
Study type: Interventional

The complement C1q tumor necrosis factor-associated protein-9 (CTRP-9), which is responsible for regulating cardiovascular and metabolic functions, increases vascular relaxation by pathway dependent on AMPK / endothelial nitric oxide synthesis (eNOS). The aim of this study was to investigate CTRP-9 levels in pregnant women with preeclampsia.